Thalomid thalidomide: Phase II data; marketed to treat moderate to severe erythema nodosum leprosum (ENL)

In a Phase II study of Thalomid to treat rapidly progressive, radioiodine-unresponsive thyroid cancers, 13 of 17 of evaluable patients with follicular or papillary thyroid cancer and 2 of 6 patients w...